×
About 598 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  194 results

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: d...
https://doi.org/10.1182/bloodadvances.2022008071
Blood Advances; Oleshko O, Werwitzke S et. al.

Aug 11th, 2022 - The root cause of autoantibody formation against factor VIII (FVIII) in acquired hemophilia A (AHA) remains unclear. We aimed to assess whether AHA is exclusively associated with autoantibodies towards FVIII, or whether patients also produce incre...

Combined Immunosuppression for Acquired Hemophilia A: CyDRi is a Highly Effective Low T...
https://doi.org/10.1182/blood.2022016873
Blood Simon B, Ceglédi A et. al.

Aug 6th, 2022 - Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant morbidity and mortality. Although critical for disease control, there is no consensus for the best immunosuppressive regimen. Most authors use steroids firs...

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid
https://www.mdedge.com/dermatology/article/256573/mixed-topics/rituximab-acquired-hemophilia-setting-bullous-pemphigoid
Maria C. Bell, MD, Daniel C. Grove, MD et. al.

Jul 28th, 2022 - To the Editor: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by the formation of antihemidesmosomal antibodies, resulting in tense bullae concentrated on the extremities and trunk that often are preceded by a pruritic u.

Challenging treatment for refractory acquired haemophilia A complicated with severe sev...
https://doi.org/10.1097/MBC.0000000000001149
Blood Coagulation & Fibrinolysis : an International Journ... Cives TL, Docampo MF et. al.

Jul 15th, 2022 - Immunosuppressive treatment and bypassing agents are used to treat acquired haemophilia A (AHA). On the other hand, COVID-19 infection induces a hypercoagulable state. Managing bleeding, risk of thrombosis, bypassing agents, active infection and i...

Immune Complications and their Management in Inherited and Acquired Bleeding Disorders.
https://doi.org/10.1182/blood.2022016530
Blood Arruda VR, Lillicrap D et. al.

Jul 7th, 2022 - Disorders of coagulation, resulting in serious risks for bleeding, may be caused by autoantibody formation or by mutations in genes encoding coagulation factors. In the latter case, anti-drug antibodies may form against the clotting factor protein...

see more →

Guidelines  1 results

International recommendations on the diagnosis and treatment of patients with acquired ...
https://doi.org/10.3324/haematol.2008.001743
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 2nd, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  11 results

Emicizumab in Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT04188639

Jun 29th, 2022 - This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (A...

Emicizumab in Patients With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT05345197

Apr 25th, 2022 - Patients with AHA who are eligible will receive two loading doses of the study drug, emicizumab (6mg/kg on day 1 and 3 mg/kg on day 2) followed by once weekly subcutaneous emicizumab (1.5 mg/kg). Immunosuppression will be given concurrently as per...

Study of TAK-672 in Participants With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT04580407

Jan 14th, 2022 - Efficacy and Safety Evaluation of B-Domain Deleted Recombinant Porcine Factor VIII (rpFVIII, TAK-672), in Japanese Participants with AHA

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
https://clinicaltrials.gov/ct2/show/NCT04805021

Jan 11th, 2022 - Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused by the sometimes ...

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
https://clinicaltrials.gov/ct2/show/NCT02610127

Aug 5th, 2021 - This study is a multi-center, uncontrolled, open-label, non-interventional post-marketing safety surveillance study to describe the use of Obizur in patients with acquired hemophilia A (AHA), and secondarily, where data are available, to describe ...

see more →

News  25 results

Rituximab for Acquired Hemophilia A in the Setting of Bullous Pemphigoid
https://www.mdedge.com/dermatology/article/256573/mixed-topics/rituximab-acquired-hemophilia-setting-bullous-pemphigoid
Maria C. Bell, MD, Daniel C. Grove, MD et. al.

Jul 28th, 2022 - To the Editor: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by the formation of antihemidesmosomal antibodies, resulting in tense bullae concentrated on the extremities and trunk that often are preceded by a pruritic u.

‘Time Is Blood’: Researchers Devise Shortcut to AHA Diagnosis
https://www.medscape.com/viewarticle/972442

Apr 20th, 2022 - Because they have detected sluggishness in hospital diagnoses, researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with me...

‘Time is blood’: Researchers devise shortcut to AHA diagnosis
https://www.mdedge.com/hematology-oncology/article/253869/bleeding-disorders/time-blood-researchers-devise-shortcut-aha
Randy Dotinga

Apr 18th, 2022 - Because they have detected sluggishness in hospital diagnoses, researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with me.

Post–COVID Vaccine AHA Cases Raise Eyebrows in Italy
https://www.medscape.com/viewarticle/968826

Feb 18th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of resear...

Post–COVID vaccine AHA cases raise eyebrows in Italy
https://www.mdedge.com/hematology-oncology/article/251919/bleeding-disorders/post-covid-vaccine-aha-cases-raise-eyebrows
Sharon Worcester

Feb 17th, 2022 - Four cases of acquired hemophilia A (AHA) identified after SARS-CoV-2 immunizations in a province in northern Italy caught the attention of researchers, who stressed that the cases are “unusual,” but not necessarily caused by vaccination. “The ove.

see more →

Patient Education  2 results see all →